Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-73763989 + NA + PegIFN-alpha-2a in Chronic Hepatitis B
NCT05005507Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 6
01
Overview
A Phase 2 trial of tomligisiran in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Started Nov 2021; status: terminated.
02
Drugs
tomligisiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05005507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005507.